

Weed and Your Workforce: What You Need to Know

National Safety Council

Ron R. Flegel, B.S., MT(ASCP), MS.

Director, Division of Workplace Program Center for Substance Abuse Prevention SAMHSA

Barry K Logan PhD, F-ABFT*

National Director, Forensic and Toxicological Services | NMS Labs

making our world safer®

© 2015 National Safety Council





Behavioral Health is Essential To Health

Prevention Works





Treatment is Effective







Weed and Your Workforce "What You Need to Know"

Presented by

Ron R. Flegel, B.S., MT(ASCP), MS. , Director Division of Workplace Programs Center for Substance Abuse Prevention Substance Abuse and Mental Health Services Administration





Outline of Presentation

- DFWP Oversight of Federal and Federally Regulated Testing
- Legalization vs. Decriminalization vs. Recreational
- Driving Under the Influence of Drugs (DUID)
- Recognize the scientific supportability of ongoing studies and future studies



Regulation



Donor

Drug Test

Result

Medical Review Officers Trained Collectors HHS-Certified Laboratories National Laboratory Certification Program Federal Agency Plan and TDP List Mandatory Guidelines

Drug Testing Advisory Board Interagency Coordinating Group Executive Committee Division of Workplace Programs Office of National Drug Control Policy Executive Order 12564 – Public Law 100-71

Drug Free Workplace Programs



ce Abuse and Mental Health Services Administration www.samhsa.gov • 1-877-SAMHSA-7

DWP Oversight



Definitions



Medical Marijuana — Permits defense against state criminal charges of marijuana possession if a medical need can be proven

Legalization— Makes possession and/or use of marijuana legal under state law



Employment: Medical Marijuana

In 2013, 32% of FT workers 18-64 years old indicated they lived in a state with laws allowing the use of medical marijuana.



Number of days marijuana was smoked in the past month



Prevalence of 30-day marijuana use by state law status



Marijuana U.S.A.

Medical, Recreational and Cannabidiol (CBD)

10





Source: diymaps.net (c)

Are We Here?



· www.clotecartoons.com



Marijuana vs. Coffee

- STARBUCKS IN L.A. COUNTY (2009) 840
- POT SHOPS IN L.A. COUNTY (2009) 966

- Los Angeles Times, Nov. 2009







Synthetic Marijuana





Synthetic Marijuana

- The main chemical used to produce synthetic marijuana is JWH-018, similar to THC
- No psychopharmacological differences exist between JWH-18 and marijuana
- Both chemicals are considered cannabinoids, which attach themselves to the *cannabinoid*, or *CB*, receptors in the brain
- However, the synthetic compounds and THC differ in levels of potency
 - Potential problem with synthetic marijuana is rapid and cost effective ability to identify the substances (analytical screening test)
 - Recognize the immediate effects (pharmacological) they may have on an individual.



Synthetic Marijuana



Marijuana Plant





CB₁ Receptors are on Axon Terminal Buttons



THC or Endocannabinoids attach to CB₁ Receptors and inhibit the release of neurotransmitters



CB₁ Synaptic Activity





NIDA Encourages Community Based Marijuana Research



Watch the video at: youtu.be/7127QLM2YWA



Herbal Incense (e.g. Spice)



K₂ K₉ Spice Gold Silver or Diamond Budda Blend, Yucatan Fire



Legal Potpourri

- Green grenade
- Clown Loyal
- Natural Spirits
- Red Planet
- Get Some Super Kush
- Red Led Leaf Herbal Potpourri
- Demon "Ritual Spicy Botanical Potpourri"
- Dark Herbal Potpourri Super Kush herbal Potpourri





The Extraction

"Dabbing" butane hash oil (BHO). Often referred to as Wax, Shatter, Honey Oil, Butane Honey Oil, Skuff and/or Kief, Hash, Liquid Solvent, Bubble Hash, Butane Hash Oil (BHO), Cannabis Oil



Watch the video at: youtu.be/3P_CEXRt010



Synthetic Marijuana THC 2000's Synthetic Cannabinoids

Dronabinol (Marinol) Nabilone (Cesamet) THC + CBD (Sativex) Cannabinol Extract (Cannador) CBD (Epidiolex) in IND-Phase III trials



Edibles and Coupons \$1 Joints in Colorado











Pot Edibles Not Medibles

Targeted for Preadolescents



Buttercrunch Pot Tarts Stoney Rancher Sodas (e.g. Joint and Bongs) KeefKat Double Puff Oeo Stoneos Gumballs





Passive Inhalation Study





Passive Study Design

- Six active smokers, six non-smokers per session
- Enclosed room with air flow control, Plexiglas walls for observation
- Smokers smoked as much as they wanted to without limitation in a "social-like" setting
- Three exposure sessions:
 - Session 1: smokers each smoke ad lib MJ cigarettes (5.3% THC) for one hour, no active air flow
 - Session 2: smokers each smoke ad lib MJ cigarettes (11.3% THC) for one hour, no active air flow
 - Session 3: smokers each smoke MJ ad lib MJ cigarettes (11.3% THC) for one hour, with active air flow simulating room air conditioning



Passive Inhalation Sessions



Session 1: 5.3% MJ, No Ventilation



Session 2: 11,3% MJ, No Ventilation



Session 3: 11.3% MJ, With Ventilation



Passive Study: Bottom Line

Extreme passive smoking is a form of drug

administration

- Estimated that non-smokers inhaled 5-15% of the amount of THC that smokers did
- Could test positive at lower cutoffs
- SAMHSA urine cutoff differentiated "passive" from "active"

Urine	Oral Fluid	Blood
Multiple positives confirmed at 20 ng/ml cutoff, but none at 50 ng/ml	Confirmed positives up to ~3 hours	Up to ~2 ng/ml
Ра	ssive Exposure Result	S A Life in





Ingestion Study





Cannabis Edibles

- Increasing popularity of oral "Edible" cannabis products
 - 16-26% of medical cannabis users
 - No combustion
 - Longer time course of effects
- Most controlled human cannabis research uses smoked/inhaled route of administration
- Federal organizations that regulate medicine food cannot regulate cannabis



(Courtesy of Ryan Vandrey, JHU)

Cannabis Brownie Preparation

- Cannabis ground into powder
- Heated for 30 min at 250°F (121°C)
- Individual doses stirred into brownie batter and baked for 30 min at 325°F (163°C)
- Individual doses of 10, 25, & 50 mg of THC



(Courtesy of Ryan Vandrey, JHU)





Edible Results: "Drug Effect"



www.samhsa.gov + 1-877-SAMHSA.7

The Pharmacokinetic Dose Effects of Oral Cannabis Administration, Urine



Note "Y" axis is log scale



The Pharmacokinetic Dose Effects of Oral Cannabis Administration, Blood



The Pharmacokinetic Dose Effects of Oral Cannabis Administration, Oral Fluid



Cannabis Edibles: Bottom Line

35

- Cannabis edibles produced severe behavioral effects
 - Behavioral effects lasted considerably longer than smoked route
 - Urine and oral fluid tests were positive
 - Blood levels of THC were extremely low and most participants who were highly impaired would not have tested positive during periods of impairment or later

Urine	Oral Fluid	Blood
 THC-COOH Cmax (ng/mL): 10 mg THC = 106 (34 - 278) 25 mg THC = 335 (75 - 729) 50 mg THC = 713 (216 - 1025) Tmax range 3-22 hrs; consistent across doses Window of detection was 74 - 216 hrs THC-COOH detectable in 6 at end of study 	 THC Cmax (ng/mL): 10 mg THC = 192 (47 - 412) 25 mg THC = 478 (70 - 1128) 50 mg THC = 598 (350 - 1010) Window of detection for THC and THCCOOH was 1.5-22, 0-126 hours respectively 	 Highest concentrations of THC was ≤ 5 ng/mL for THC; only 2 participants @ 50 mg THC achieved 5 ng/mL No THC detected for 2 participants (10 mg) Cmax THCCOOH (ng/mL) 10 mg THC = 7 (5 - 14) 25 mg THC = 21 (12 - 39) 50 mg THC = 29 (16 - 44)

Edible Results



Ongoing and Future Studies

- Oral Cannabis Ingestion
- DUID POCT Device Evaluation
- Synthetic Opiates / MRO Review Process for Oral Fluid / Urine
- Oral Fluid Collection Device Stability / Marijuana Recovery
- Marijuana Decriminalization vs. Legalization
- Federal Program Evaluations (NTSB, NHTSA, DOT, NRC, etc.)
- Other scientific, legal, and public policy concerns for safety sensitive positions around Marijuana



Considerations

Drug Testing will continue to face difficult and challenging issues related to the changing landscape of marijuana legalization and decriminalization in the federal, state, local, and community levels and at the workplace.

As states modify marijuana laws, non Federal workplaces will need to review and possibly adjust their drug free workplace policies but drugs impair performance in the workplace

Discussion needs to be continued about current and future research, policy, and legal issues related to the changing landscape of marijuana legalization and decriminalization efforts and shifting knowledge and findings.







Resources:

Drug Fact Sheet K2 or Spice. (2011, March 4). Retrieved from <u>http://www.dea.gov/druginfo/drug_data_sheets/K2_Spice.pdf</u> Drug Enforcement Administration

DrugFacts: Synthetic Cannabinoids. (2015, November). Retrieved February, 2016, from http://www.drugabuse.gov/publications/drugfacts/synthetic-cannabinoids National Institute on Drug Abuse; National Institutes of Health; U.S. Department of Health and Human Services

Hash oil explosions on the rise in Colorado . (2014, May). Retrieved March, 2016, from https://www.youtube.com/watch?v=3P_CEXRt010 7 NEWS – The Denver Channel; Youtube

Williams, Dr. (Speaker). (2014, November). NIDA Encourages Community Based Marijuana Research [Video file]. Retrieved February, 2016, from <u>http://www.drugabuse.gov/videos/nida-encourages-community-based-marijuana-research</u> National Institute on Drug Abuse; The Science of Drug Abuse & Addiction









DWP phone number: (240) 276-2600

Executive Order 12564: http://beta.samhsa.gov/sites/default/files/executive_order.pdf

Public Law 100-71: http://beta.samhsa.gov/sites/default/files/workplace/public law 100.pdf

Mandatory Guidelines: http://www.gpo.gov/fdsys/pkg/FR-2008-11-25/pdf/E8-26726.pdf

Model Plan for a Comprehensive Drug-Free Workplace Program: http://beta.samhsa.gov/sites/default/files/workplace/ModelPlan508.pdf

2013 Guidance for Selection of Testing Designated Positions: <u>http://beta.samhsa.gov/sites/default/files/workplace/2013_guidance_selection_TDPs_4_26_2013.pdf</u>





Weed and Your Workforce: What You Need to Know Prevalence and Impairment

Barry K Logan PhD, F-ABFT*

NMS Labs

Center for Forensic Science Research and Education





Please ask Yourself

- What is known about the impact of legalization of marijuana on rates of use and Prevalence?
- What Effects of marijuana are relevant in the workplace?
- How do Synthetic Cannabinoids fit into the picture?
- What are some considerations around Testing?

Prevalence

Cannabis Use

• Perceived "Great Risk" of Marijuana Use (Youth 12-17)



Cannabis Use

• Individuals reporting daily or almost daily cannabis use.



National Workplace Drug Testing

US General Workforce, pre-employment 9.1M

Drug Category	2010	2011	2012	2013	2014
6-AM	0.011% ¹	0.013%	0.017%	0.020%	0.025%
Amphetamines	0.58%	0.69%	0.77%	0.85%	0.90%
Barbiturates	0.25%	0.26%	0.25%	0.23%	0.22%
Benzodiazepines	0.79%	0.78%	0.73%	0.74%	0.71%
Cocaine	0.25%	0.28%	0.23%	0.23%	0.24%
Marijuana	1.7%	1.6%	1.6%	1.7%	1.9%
Octoper - December	2010				

"Marijuana positivity increases

nationally for the second

consecutive year." (11% increase)

Dr. Barry Sample, Quest Diagnostics

http://www.employer-solutionsresources.com/whitepaper/2015-drug-testingindex

Cannabis Use by Drivers

• National Roadside Survey 2013

Table 2 Overall Drug Prevalence by Data Collection Period and Type of Test in the 2013–2014 NRS

Time of Day	% Drug-Positive Oral Fluid Test	% Drug-Positive Blood Test	% Dı Fluid	rug-Positiv and/or Blo	e Oral od Test
Weekday Daytime	19.0%	21.6%		22.4%	
Weekend Nighttime	19.8%	21.2%		22.5%	



Cannabis Use by Drivers

• National Roadside Survey 2013

Table 4

Weekend Nighttime Drug Prevalence by Drug Category and Test Type Comparing 2007 Data to 2013–2014 Comparable Data

2007 Data						2013–2014 Comparable Data						
Oral Fluid Test		Blood	Oral Fluid and/or Blood Test Blood Test		C	Dral Fl	uid Test	Blood	l Test	Oral Flu Bloo	id and/or d Test	
N	%	N	%	N	%		Ν	%	Ν	%	N	%
635	11.4%	297	9.8%	699	12.4%	Γ	779	13.8%	422	14.3%	849	15.1%
201	3.0%	169	4.0%	277	3.9%		211	3.9%	155	4.9%	266	4.9%
	Oral Flu N 635 201	Oral Fluid Test N % 635 11.4% 201 3.0%	Oral Fluid Test Blood N % N 635 11.4% 297 201 3.0% 169	Oral Fluid Test Blood Test N % % 635 11.4% 297 9.8% 201 3.0% 169 4.0%	2007 Data Oral Fluid Test Blood Test Oral Fluid Blood N % N % 635 11.4% 297 9.8% 699 201 3.0% 169 4.0% 277	Dral Fluid Test Oral Fluid and/or Blood Test N % N % 635 11.4% 297 9.8% 699 12.4% 201 3.0% 169 4.0% 277 3.9%	Dral Fluid Test Oral Fluid and/or Blood Test 0300 11.4% 297 9.8% 6999 12.4% 12.4% 12.4% 12.4% 12.4% 12.4% 12.4% 12.4% 12.4% 12.4%	2007 Data Oral Fluid Test Blood Test Oral Fluid and/or Blood Test Oral Fluid N N % N % N 635 11.4% 297 9.8% 699 12.4% 779 201 3.0% 169 4.0% 277 3.9% 211	Oral Fluid Test Blood Test Oral Fluid and/or Blood Test Oral Fluid Test Oral Fluid Test N % N % N % N % 635 11.4% 297 9.8% 699 12.4% 779 13.8% 201 3.0% 169 4.0% 277 3.9% 211 3.9%	2007 Data 2013–2014 col Oral Fluid Test Blood Test Oral Fluid and/or Blood Test Oral Fluid Test Blood N % N % N % N % N % N % N % N % N % N % N % N % N % N % N % N % N % N % N %	2007 Jata 2013–2014 colliparable Oral Fluid Test Oral Fluid and/or Blood Test Oral Fluid Test Oral Fluid Test Blood Test N % N % N % N % N % 14.3% 635 11.4% 297 9.8% 699 12.4% 779 13.8% 422 14.3% 201 3.0% 169 4.0% 277 3.9% 211 3.9% 155 4.9%	Oral Fluid Test Blood Test Oral Fluid and/or Blood Test Oral Fluid Test Oral Fluid Test Blood Test Blood Test Oral Fluid Test Blood Test

Table 5 Weekend Nighttime Prevalence of THC in 2007 Compared to 2013–2014 Comparable Data

2007 Data						2013-2014	Comparab	le Data			
Oral Flu	uid Test	Blood	l Test	Oral Fluid an	/or Blood Test	Oral Fl	uid Test	Blood	l Test	Oral Fluid an	or Blood Test/
Ν	%	N	%	N	%	N	%	N	%	N	%
438	7.7%	234	7.6%	499	8.6%	597	11.3%	332	11.7%	663	12.6%



Marijuana DUI

Colorado – Post Legalization

SECTION 1: Impaired Driving Data

"MARIJUANA CITATIONS DEFINED AS ANY CITATION WHERE CONTACT WAS CITED FOR DRIVING UNDER THE INFLUENCE (DUI) OR DRIVING WHILE ABILITY IMPAIRED (DWAI) AND MARIJUANA INFORMATION WAS FILLED OUT ON TRAFFIC STOP FORM **INDICATING MARIJUANA & ALCOHOL. MARIJUANA & OTHER CONTROLLED** SUBSTANCES, OR MARIJUANA ONLY PRESENT BASED ON OFFICER OPINION ONLY (NO TOXICOLOGICAL CONFIRMATION)." - COLORADO STATE PATROL

Colorado State Patrol Number of DUIDs, 2014



http://www.rmhidta.org/html/2015%20PRE VIEW%20Legalization%20of%20MJ%20in %20Colorado%20the%20Impact.pdf

Marijuana DUI

• Washington – Post Legalization

"We have seen marijuana Table 1: involvement in fatal crashes remain steady over the years, and then it just spiked in 2014. From 2010-2014, nearly 60 percent of drivers involved in fatal collisions were tested for drugs. Among these tested drivers, approximately 20 percent (349 drivers) were positive for marijuana." Dr. Staci Hoff. WTSC Data and

Research Director

Percentage of total driving cases confirming positive for THC (delta-9-THC)

Year	Total # of impaired	Percentage of total
	driving cases received	cases testing positive
	for testing	for THC
2009	4,809	18.2 %
2010	5,012	19.4 %
2011	5,132	20.2 %
2012	5,298	18.6 %
2013	5,468	24.9 %
2014	6,270	28.0 %
2015 (Jan-Apr)	2,231	33.0 %

http://wtsc.wa.gov/News/marijuanaincreased-in-2014-as-a-factor-in-deadlycrashes/

Intoxication – Synthetic Cannabinoids

THE TRIBUNE

Driver in fatal Highway 1 crash allegedly smoked synthetic marijuana

Los Osos resident Tanner Mengore, 22, faces charges of DUI, manslaughter

BY NICK WILSON

nwilson@thetribunenews.com October 25, 2014



"The driver in a deadly weekend crash that has devastated a local family was under the influence of synthetic marijuana, also known as "spice," according to the CHP".

Intoxication – Syn Canns



Police: School bus driver high on synthetic marijuana during multi-vehicle crash

POSTED 11:24 AM, APRIL 22, 2015, BY DALLAS FRANKLIN, UPDATED AT 05:27PM, APRIL 22, 2015



"OKLAHOMA CITY – A local school bus driver who crashed into multiple cars in southeast Oklahoma City, leaving three people hospitalized, was reportedly high on synthetic marijuana at the time.

Driving Case Studies

Blood synthetic cannabinoid concentrations in cases of suspected impaired driving.

Yeakel JK, Logan BK. J Anal Toxicol. 2013 Oct;37(8):547-51.

- 12 cases of Suspected impaired driving involving synthetic cannabinoids.
- Attitude of the drivers was cooperative and relaxed, speech was slow and slurred, coordination was poor.
- Pulse and blood pressure were generally elevated.
- The most consistent sign noted was a marked lack of convergence in all cases where it was assessed.
- JWH-018 (n=4), 0.1-1.1ng/mL; JWH-081 (n=2) qualitative only; JWH-122 (n=3) 2.5ng/mL; JWH-210 (n=4) 0.1ng/mL; JWH-250 (n=1) 0.38ng/mL; AM-2201 (n=6) 0.43 4.0ng/mL.

Effects

Cannabinoid Pharmacology

Acute Psychoactive Effects

- Euphoria
- Relaxation/Stress Reduction
- Enhanced Perception
 - Music, Humor, Arts



- Illusions/Pseudohallucinations
- Time Distortion
- Ataxia
- Anxiety, Paranoia, Illusions, Depersonalization



Cannabis and Impairment

Well known **Cognitive** effects include:

Concentration and sustained attention/vigilance.
Fatigue, sleepiness, lethargy, memory problems.
Reaction time

- Difficulty in thinking and problem-solving.
- Difficulty in registering, processing, and using information.



Cannabis and Impairment

Sevent Well Known Performance Effects Include

- Section Attention
- Section 2 Vigilance
- Section 24 Arousal
- Seaving Weaving
- Selimpulsivity
- Reaction Time



Testing

NSC 2013 Recommendations



Recommendations for Toxicological Investigation of Drug-Impaired Driving and Motor Vehicle Fatalities

Barry K. Logan^{1,2}*, Kayla J. Lowrie¹, Jennifer L. Turri¹, Jillian K. Yeakel¹, Jennifer F. Limoges³, Amy K. Miles⁴, Colleen E. Scarneo⁵, Sarah Kerrigan⁶ and Laurel J. Farrell⁷

¹Center for Forensic Science Research and Education, Fredric Rieders Family Renaissance Foundation, Willow Grove, PA, USA, ²NMS Labs, Willow Grove, PA, USA, ³New York State Police Forensic Investigation Center, Albany, NY, USA, ⁴Wisconsin State Laboratory of Hygiene, Madison, WI, USA, ⁵New Hampshire Department of Safety, Division of State Police Forensic Laboratory, Concord, NH, USA, ⁶Sam Houston State University, Huntsville, TX, USA, and ⁷Toxicologist/Consultant, Longmont, CO, USA



J Anal Toxicol. 2013 Aug 13

NSC 2013 Recommendations



>Included Oral Fluid for the first time.

- ➤ Refined the list of recommended targets, which now includes a total of 33 drugs and metabolites.
- >Includes Cannabis, Stimulants, CNS depressants, Narcotic Analgesics, Dissociative Drugs.
- Identifies selected immunoassay tests to cover this scope:

Recommended Immunoassays					
Cannabis	Carisoprodol				
Methamphetamine	Zolpidem				
Amphetamine	Barbiturates				
Cocaine/Metabolite	Methadone				
Benzodiazepines	Opiates				
- plus lorazepam, clonazepam	Oxycodone				
	PCP				



NSC 2013 Recommendations



Structure:

- <u>Tier 1: Minimum Standard</u>
- Prevalent compounds most frequently associated with DUID:
 - Marijuana, cocaine, amphetamines, PCP, benzodiazepines, opioids, muscle relaxants, sedatives, anticonvulsants.

• <u>Tier 2: Supplemental Analysis</u>

- Emerging compounds, less prevalent, regional, less evidence for impairing effects:
 - Cathinones, antipsychotics, other antidepressants, synthetic cannabinoids

What You Need to Know...

- Public view of marijuana is changing from a "gateway drug", to a lifestyle choice, and alternative medicine.
- Broad indicators of increasing rates of use of marijuana in US populations, including workplace and driving.
- Synthetic Cannabinoids are on the rise also.
- Evidence of impairing effects is well established and most profound in the 2-4, or 6-8 hours following single acute use.
- Effects include diminished attention, judgment and control, vigilance, and reaction time – significant workplace safety concerns.
- More testing options, especially on-site, and broader scope will help address DUID and workplace safety concerns.



- nsc.org/rxpainkillers (RX webpages)
- **nsc.org/rxactionkit** (Community Action Kit)
- **nsc.org/rxemployerpolicy** (Employer Kit)
- nsc.org/painmedevidence (report)
- safety.nsc.org/sideeffects (report)
- nsc.org/workerscomp (report)
- **nsc.org/prescriptionnation** (infographic)
- **nsc.org/hiddenepidemic** (infographic)
- **nsc.org/nnt** (infographic)



NSC Prescription Drug Initiative Team

Don Teater (630) 775-2125 Don.Teater@nsc.org

Tess Benham (630) 775-2159 <u>Tess.Benham@nsc.org</u>

© 2015 National Safety Council



Questions and Discussion

Ron R. Flegel, B.S., MT(ASCP), MS. ron.flegel@samhsa.hhs.gov

Barry K Logan PhD, F-ABFT* barry.logan@nmslabs.com

© 2015 National Safety Council

making our world safer*